[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].

1. Wilson Di, cross iE, Wren c, Scambler PJ, Goodship J. Minimum prevalence of 22q11 deletions. Am J Hum Genet. 1994;55:A169. 2. tézenas Du Montcel S, Mendizabai H, Aymé S, Lévy A, Philip N. Prevalence of 22q11 microdeletion. J Med Genet. 1996;33:719. 3. ryan AK, Goodship JA, Wilson Di, Philip N, LevyA, Seidel H, et al. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. J Med Genet. 1997;34:798-804. 4. Di George AM. congenital absence of the thymus and its immunological consequences: concurrence with congenital hypoparathyroidism. Birth Defects. 1968;4:116-21. 5. Moreno izco f, Zuazo Zamalloa E, González Alvarado S, Bereciartu irastorza P. Síndrome de deleción 22q11: un fenotipo en expansión. Neurología. 2009;24:69-71. 6. Gothelf D, frisch A, Michaelovsky E, Weizman A, Shprintzen rJ. Velo-cardio-facial Síndrome. J Ment Health res intellect Disabil. 2009;2:149-67. 7. robin NH, Shprintzen rJ. Defining the clinical spectrum of deletion 22q11.2. J Pediatr. 2005;147:90-6.